Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Arthritis, Rheumatoid 4Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Hematologic Neoplasms 3Leukemia 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Stomach Neoplasms 1Spondylitis, Ankylosing 1Solid Tumors 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Mesothelioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphohistiocytosis, Hemophagocytic 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1

Interventions

tocilizumab 1siltuximab 1Zidovudine 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multi-centric Castleman's Disease × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡